跳轉至內容
Merck
全部照片(1)

重要文件

1724500

USP

齐多夫定

United States Pharmacopeia (USP) Reference Standard

同義詞:

3′-叠氮-3′-脱氧胸苷, AZT, ZDV, 叠氮胸苷, 齐多夫定

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C10H13N5O4
CAS號碼:
分子量::
267.24
Beilstein:
3595791
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

zidovudine

製造商/商標名

USP

mp

113-115 °C (lit.)

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O

InChI

1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1

InChI 密鑰

HBOMLICNUCNMMY-XLPZGREQSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Zidovudine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Abacavir, Lamivudine and Zidovudine Tablets
  • Lamivudine and Zidovudine Tablets
  • Zidovudine
  • Zidovudine Capsules
  • Zidovudine Injection
  • Zidovudine Oral Solution
  • Zidovudine Tablets

生化/生理作用

对 HIV-1 病毒有效的逆转录酶抑制剂。

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Health hazard

訊號詞

Warning

危險聲明

危險分類

Carc. 2 - Muta. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Y-H Lai et al.
Gene therapy, 22(2), 155-162 (2014-10-31)
Replicating virus vectors are attractive tools for anticancer gene therapy, but the potential for adverse events due to uncontrolled spread of the vectors has been a major concern. To design a tumor-specific retroviral replicating vector (RRV), we replaced the U3
H Stedt et al.
Cancer gene therapy, 22(3), 130-137 (2015-01-24)
Malignant gliomas (MGs) are the most common malignant primary brain tumors with a short life estimate accompanied by a marked reduction in the quality of life. Herpes Simplex virus-1 thymidine kinase ganciclovir (HSV-TK/GCV) system is the best characterized enzyme prodrug
Youko Suehiro et al.
British journal of haematology, 169(3), 356-367 (2015-01-24)
Adult T cell leukaemia/lymphoma (ATL) is a human T cell leukaemia virus type-I (HTLV-I)-infected T cell malignancy with poor prognosis. We herein developed a novel therapeutic vaccine designed to augment an HTLV-I Tax-specific cytotoxic T lymphocyte (CTL) response that has
Roger Badia et al.
Antimicrobial agents and chemotherapy, 58(8), 4318-4327 (2014-05-14)
Genome editing using zinc finger nucleases (ZFNs) has been successfully applied to disrupt CCR5 or CXCR4 host factors and inhibit viral entry and infection. Gene therapy using ZFNs to modify the PSIP1 gene, which encodes the lens epithelium-derived growth factor
Richard M Hoglund et al.
British journal of clinical pharmacology, 79(4), 636-649 (2014-10-10)
Drug-drug interactions between antimalarial and antiretroviral drugs may influence antimalarial treatment outcomes. The aim of this study was to investigate the potential drug-drug interactions between the antimalarial drugs, lumefantrine, artemether and their respective metabolites desbutyl-lumefantrine and dihydroartemisinin, and the HIV

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務